Major Players Swap Positions Among Industry Top 50
Key Developments Lead To Ups And Downs In The Middle Of Our Ranking
The second part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies sees a number of major firms sliding up and down the table.
You may also be interested in...
Careful supply-chain planning and an agile, flexible approach to manufacturing have been key in helping Hikma to stay on top of the “rollercoaster ride” provided by the COVID-19 pandemic in 2020 so far, according to CEO Siggi Olafsson.
This article brings you a compilation of all the data from Generics Bulletin's recent ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.
In the third and final part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies, one or two new entrants appeared towards the bottom of the top 50.